Table 2 Predictors of response
From: Outcome of adalimumab monotherapy in paediatric non-infectious uveitis
Failed adalimumab monotherapy (N = 5) | Maintained adalimumab monotherapy (N = 23) | p value | |
|---|---|---|---|
Gender, Female, n (%) | 3 (60.0) | 12 (52.2) | 1.00 |
Ethnicity | |||
White British, n (%) | 3 (60.0) | 21 (91.3) | 0.14 |
Others, n (%) | 2 (40.0) | 2 (8.7) | |
Anatomical distribution of uveitis type, n (%) | |||
Anterior | 3 (60.0)* | 21 (91.3) | < 0.05 |
Intermediate | 3 (40.0)* | 2 (8.7) | |
Uveitis presentation, n (%) | |||
Symptomatic | 0 (0) | 3 (13.0) | 1.00 |
Asymptomatic | 5 (100) | 20 (87.0) | |
Uveitis laterality, n (%) | |||
Unilateral | 2 (40.0) | 5 (21.7) | 0.57 |
Bilateral | 3 (60.0) | 18 (78.2) | |
Underlying diagnosis, n (%) | |||
JIA | 2 (40.0) | 13 (56.5) | 0.64 |
Idiopathic | 3 (60.0) | 10 (43.5) | |
ANA positive JIA patients (n/N) | 2/2 | 5/5 | 1.00 |
Age at diagnosis of uveitis (years), median (IQR) | 5.0 (7.0) | 6.0 (6.0) | 0.89 |
Uveitis duration before adalimumab monotherapy (months), median (IQR) | 50.0 (38.0) | 48.0 (34.5) | 0.68 |
Total duration of adalimumab (including monotherapy period, months) median (IQR) | 39.0 (34.0) | 33.0 (41.0) | 0.71 |
Duration of adalimumab before monotherapy, months, median (IQR) | 30 (30) | 17 (28) | 0.10 |
Duration of adalimumab monotherapy, months, median (IQR) | 9 (3.5) | 20 (19) | < 0.05 |
Type of Immunosuppressive drug prior to adalimumab monotherapy, n (%) | |||
MTX | 5 (100) | 16 (70.0) | 0.29 |
MMF | 0 (0) | 0 (0) | 1.00 |
MTX plus MMF | 0 (0) | 6 (26.1) | 0.55 |
Systemic steroid | 0 (0) | 0 (0) | 1.00 |
Etanercept | 0 (0) | 1 (4.3) | 1.00 |
Baseline AC cells (number of patients/ number of eyes) | |||
0 | 5/10 | 32/46 | 0.28# |
0.5 + | 5/10 | 9/46 | |
1 + | 0/10 | 4/46 | |
2 + | 0/10 | 0/46 | |
3 + | 0/10 | 1/46 | |
4 + | 0/10 | 0/46 | |
Baseline Intraocular pressure, n (%) | |||
Normal | 9 (90.0) | 46 (100) | 0.18 |
> 21 mmHg | 1 (10.0) | 0 (0) | |
Baseline Number of glucocorticoid drops per eye per day, n (%) | |||
≤ 3 | 10 (100) | 40 (87.0) | 0.58 |
> 3 | 0 (0) | 6 (13.0) | |
Baseline Visual Impairment (number of eyes) | |||
≤ 0.3 logMAR | 10/10 | 46/46 | 1.00 |
> 0.3 logMAR | 0/10 | 0/46 | |
Baseline Ocular complication/surgeries (number of patients) | 4/5 | 8/23 | 1.00 |
Cataract | 2/5 | 4/23 | 0.29 |
Band keratopathy | 1/5 | 0/23 | 0.18 |
Retinal detachment | 0/5 | 1/23 | 1.00 |
Glaucoma | 1/5 | 1/23 | 1.00 |
Posterior synechiae | 0/5 | 2/23 | 1.00 |
Ocular procedure/surgery | 1/5 | 3/23 | 1.00 |